

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 May 2025 (30.05.2025)



(10) International Publication Number
WO 2025/108446 A1

(51) International Patent Classification:

<i>C07K 16/30</i> (2006.01)	<i>C12N 1/15</i> (2006.01)
<i>C07K 16/28</i> (2006.01)	<i>C12N 1/19</i> (2006.01)
<i>C12N 5/10</i> (2006.01)	<i>C12N 1/21</i> (2006.01)
<i>C12N 15/13</i> (2006.01)	<i>A61K 39/395</i> (2006.01)
<i>C12N 15/11</i> (2006.01)	<i>A61K 39/00</i> (2006.01)
<i>C12N 15/63</i> (2006.01)	<i>A61P 35/00</i> (2006.01)

(21) International Application Number:

PCT/CN2024/133902

(22) International Filing Date:

22 November 2024 (22.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/133687

23 November 2023 (23.11.2023) CN

PCT/CN2024/088974

19 April 2024 (19.04.2024) CN

(71) Applicant: **LANOVA MEDICINES LIMITED** [CN/CN]; Cailun Road, Building 1, Floor 5, Pudong New Area, Shanghai 201203 (CN).

(72) Inventors: **LI, Runsheng**; Cailun Road, Building 1, Floor 5, Pudong New Area, Shanghai 201203 (CN). **HUANG, Wentao**; Cailun Road, Building 1, Floor 5, Pudong New Area, Shanghai 201203 (CN). **ZANG, Ying Qin**; Cailun Road, Building 1, Floor 5, Pudong New Area, Shanghai 201203 (CN).

(74) Agent: **SINO-CREATIVITY INTELLECTUAL PROPERTY LAW FIRM**; Room 23A03, Block 4, the Place Tower, No. 9 Guanghai Road, Chaoyang District, Beijing 100020 (CN).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTI-CDH17 ANTIBODIES AND CONJUGATES THEREOF

(57) Abstract: Provided are antibodies or antigen-binding fragment thereof having binding specificity to the human cadherin 17 (CDH17) protein and antibody-drug conjugates (ADC) thereof. These antibodies and ADCs are capable of binding to CDH17 with high selectivity, bystander effect and anti-tumor effect. Also provided are methods and uses for treating cancers.

WO 2025/108446 A1